Media

Anesiva Announces That FDA Grants Orphan Drug Status for Pain Drug 4975 to Treat Interdigital Neuroma

Long-Lasting Effect of 4975 Provides Weeks of Pain Relief After Single Injection to Treat Chronic Foot Pain Associated With Inflamed Nerve Tissue

SOUTH SAN FRANCISCO, Calif., Oct 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug status to product candidate 4975 for the treatment of a painful condition in the foot known as interdigital neuroma in patients who fail conservative treatments, such as foot pads, NSAID's (non-steroidal anti-inflammatory drugs) and injections of corticosteroids, that would otherwise require removing or chemically destroying the nerve that causes the pain. Orphan drug designation is granted by the FDA to encourage companies to develop products that treat rare diseases and conditions and includes incentives such as market exclusivity for seven years, tax credits on qualified clinical trial expenses and a waiver of the FDA prescription drug user fees.

"4975 has shown great promise in a number of indications, and the potential to treat the serious pain associated with interdigital neuroma, sometimes referred to as Morton's neuroma, offers an important opportunity for us. There are no drugs approved to treat this unmet medical need. This condition afflicts approximately 200,000 new patients in the United States each year with about half of them failing conservative therapy," said John P. McLaughlin, chief executive officer of Anesiva. "The long duration of action following a single localized administration of 4975 offers a unique treatment option to patients with various types of post-surgical, neuropathic and musculoskeletal pain conditions by providing pain relief for several weeks following a single injection without the side effects associated with other pain medications."

Interdigital Neuroma and 4975

Interdigital neuroma is highly painful and has been described as feeling like walking on a hot pebble or having a hot poker thrust between the toes. This type of post-traumatic neuropathic pain is most often caused by compression of the nerves between the foot bones from running, wearing high narrow shoes and excessive standing. Treatment for interdigital neuroma currently includes orthotics, non-steroidal pain relievers and steroid injections, which fail in approximately 50 percent of patients. Surgical removal of the neuroma may lead to lengthy painful rehabilitation, and like other treatment options that chemically destroy the affected nerve, result in permanent numbness in that portion of the foot. In some instances, the neuroma regrows causing a return of this painful condition.

Data from a Phase 2 clinical trial in patients with interdigital neuroma who previously failed treatments with conservative options, such as orthotics and steroid injections, demonstrated that 4975 produced a statistically significant reduction in foot pain for four weeks following a single injection when compared to placebo treatment.

How 4975 May Address Need for Long-Duration, Well-Tolerated Pain Relief

4975 is long-acting, with the potential to provide pain relief for weeks or months after just a single localized treatment. It is a non-opioid TRPV1 agonist with a unique mechanism of action that provides a long-lasting, localized effect on C-fibers and blocks the transmission of aching, throbbing pain caused by major surgical procedures. Because it selectively acts on pain-sensing nerve endings, 4975 does not affect other nerve fibers necessary for sensory or motor sensations, such as those needed to sense temperature or pressure.

In clinical studies to date, 4975 has not had the side effects often associated with other conventional pain medications and has been shown to be well tolerated. Opioid drugs, such as morphine, which are commonly used agents to relieve pain in post-surgical and musculoskeletal pain conditions, have significant side effects including sedation, respiratory depression, euphoria, and nausea and vomiting during acute use, and constipation and physical dependence during chronic use.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications, the most advanced of which, Zingo(TM), has completed Phase 3 clinical trials. The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. 1207, a new local anesthetic that is undergoing preclinical development as a topical local anesthetic, is anticipated to enter the clinic in 2006. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to www.anesiva.com .

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, projected timing of FDA filings and clinical data announcements and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Anesiva can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward- looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended June 30, 2006.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

SOURCE Anesiva, Inc.

Jennifer Cook Williams, Vice President, Investor Relations of Anesiva,
+1-650-624-9600, or [email protected]

http://www.anesiva.com/

News Provided by COMTEX